Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and PD-1/L1 Inhibitor after Chemotherapy for ES-SCLC (AVATAR)
NCT04313660Phase 2Unknown
- Start
- Apr 2020
- Primary completion
- Feb 2021
01
Overview
A Phase 2 trial of anlotinib in small cell lung cancer (SCLC). Status: unknown.
02
Drugs
anlotinib
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04313660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04313660.